CLINIC VISITS AND HOSPITAL ADMISSIONS FOR CARE OF ACID-RELATED UPPER GASTROINTESTINAL DISORDERS IN WOMEN USING ALENDRONATE FOR OSTEOPOROSIS

Context: About 1 in 3 women taking alendronate for osteoporosis report gastrointestinal symptoms, a rate much higher than that found during clinical trials.Objective: To establish the frequency of outpatient vi sits and hospital admissions for acid-related upper gastrointestinal d isorder (ARD) among women taking alendronate and to identify potential risk factors. Methods: A retrospective database analysis identified 8 12 women with osteoporosis who had filled one or more 10-mg alendronat e prescriptions from October 1995 through October 1996. Results: One h undred (12.3%) of the 812 women received healthcare for ARD, a clinica l encounter rate of 28.5 per 100 person-years. A reference group of 36 2,109 women from the same health plan had 17.6 ARD encounters per 100 person-years. Excluding women who had ARDs before receiving alendronat e, alendronate users were 1.6 (95% CI=1.2, 2.7) times more likely to h ave an ARD encounter than nonusers. Risk of having ARD increased with age [users aged 70 years and older had a relative risk of 1.5 (95% con fidence interval (CI) 1.0-2.30) compared with younger women] and with concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDS) (relat ive risk 1.7, 95% CI 1.1-2.6). Conclusions: Elderly alendronate users or those concurrently taking NSAIDS should be carefully monitored beca use of their high risk of having ARD. Cost/benefit analyses of alendro nate treatment for osteoporosis should include costs of treating ARD.